Introduction
Severe aortic stenosis (AS) affects 2-4% of adults older than 75 years of age. [1] [2] [3] Current guidelines recommend surgical aortic valve replacement (SAVR) as the firstline therapy for patients who are appropriate surgical candidates. Traditionally, transcatheter aortic valve
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replacement (TAVR) is recommended for patients who are not surgical candidates. 4 However, in recent years TAVRs have been increasing in popularity. 5 The OBSERVANT trial demonstrated no significant difference in mortality between SAVR and TAVR at 1 year in patients matched head to head, many of which had a more favorable risk profile than is typical of most TAVR patients. 6 TAVR is quickly gaining widespread use with the potential for expanded indications. Thus, any potential complication needs to be thoroughly characterized. High-degree atrioventricular (AV) block requiring permanent pacemaker implantation (PPI) is an important and well-known complication of TAVR. This complication happens more frequently in TAVR than in SAVR. [7] [8] [9] The OBSERVANT study demonstrated a 3.6% versus 15.5% (po0.001) pacemaker implantation rate for SAVR versus TAVR. 6 The study included patients that underwent TAVR with either the Edwards SAPIEN' valve (Edwards Lifesciences, Irvine, CA) or the Medtronic CoreValve' (Medtronic Inc., Minneapolis, MN). Current literature has shown that these two devices have very different post-procedural PPI rates. Studies have found a PPI rate of 18-34% for the CoreValve' versus 4-12% for the SAPIEN' valve (Edwards Lifesciences, Irvine, CA). [9] [10] [11] [12] [13] [14] [15] [16] [17] Additionally, the CoreValve' has been associated with a higher incidence of procedural related left bundle branch block (LBBB) than the SAPIEN'. [16] [17] [18] [19] [20] It is not yet fully understood what causes these marked differences. Although the CoreValve' is more likely to cause conduction abnormalities than SAPIEN' valve, this has not manifested itself in overall mortality. Neither the UK-TAVI or the FRANCE-2 trial reveal a significant difference in mortality between the two valves. 21, 22 The majority of data suggests a neutral effect, but there is evidence that patients who require PPI after TAVR have a higher mortality at 1 year than patients who did not require pacemaker implantation. 23 A subgroup analysis from the PARTNER study also demonstrates that PPI was associated with lower ejection fractions at 1 year. 23 Thus, in patients with severe aortic stenosis undergoing TAVRs, it is important to identify which patients are at high risk for post-procedure PPI to better tailor their management and therapies. Patients who receive therapy after commercial release may show differences with expanded indications or without the stringent guidelines of a Pivotal Trial. Thus, complication rates may be different in this group. Moreover, next-generation devices may also differ and their complication rates should be validated in a real-world population. For this reason, we sought to analyze the PPI rate in our large, single-center CoreValve' (Medtronic Inc., Minneapolis, MN) experience, and compare rates between those enrolled in the Pivotal Trial with those implanted since approval.
Materials and methods
This was a retrospective study that analyzed a cohort of patients who underwent TAVR at the University of Southern California Keck Medical Center from July 2011 to May 2016. The protocol was reviewed and approved by our Institutional Review Board. A total of 178 patients underwent TAVR during this time period. All TAVR procedures were performed using a self-expanding CoreValve' or Evolut' system; the procedure approach was selected at the discretion of the attending physicians. Valves were implanted through a retrograde transfemoral direct aortic approach. Sixty of the patients included were part of the United States Pivotal Trial (study patients) and 91 of the patients received the CoreValve' after Federal Drug Administration approval. Thirty-two patients received the Evolut' next-generation valve. Twenty-five patients from the study group and 13 from the commercial group were excluded because they either had a prior permanent pacemaker/defibrillator or their TAVR was converted into a surgical replacement mid-procedure (18/25 and 7/ 25 from the study group; 11/13 and 2/13 from the PMA group, respectively). Five patients were excluded from the Evolut' group for prior pacemaker implantation. For each patient, demographic, electrocardiogram, past medical and surgical history, home medications, and post-procedural pacing parameters were recorded.
Statistical analysis
Categorical data are presented as number and percentage, and continuous variables are presented as the mean±standard deviation. Statistical analysis was performed using the SAS version 9.2 (SAS Institute Inc). The Student t test was used to compare continuous variables, and the chi-square test or Fisher exact test was used to compare categorical variables. Univariate and multivariate analyses by logistic regression were conducted to identify variables independently associated with pacemaker implant. Using stepwise logistic regression analysis, the following variables from univariate analysis were entered into a multivariate model: age, gender, QRS4120, prior conduction disease, prior atrial fibrillation (AF) and balloon valvuloplasty. All probabilities were two-sided, and pr0.05 was considered significant.
Results
In total 140 patients were analyzed. Table 1 shows the baseline characteristics for the total patient population and subgroups. The average age in the total population was 81.2±8.9 years. The average age in the Pivotal Trial population was older than either the PMA group or the Evolut' group (85.1 ± 8.0 versus 80.2 ± 9.0 and 78.7 ± 8.1, p ¼ 0.0006). Fifty-six percent of the PMA group and 54% of the Pivotal Trial group were male as opposed to 29.6% in the Evolut' group (p ¼ 0.04). There was no significant difference in the proportion of patients with prior conduction disease between the two groups, nor in the percentage of patients with history of coronary artery bypass or other cardiac procedure. A higher percentage of the patients in the Evolut' group were on b-blockers. Table 2 shows the rate of pacemaker implantation. The overall rate of pacemaker implantation was 39.3% in the total population. The most common indication for pacemaker in the entire population was third-degree heart block (53%). There was no significant difference in pacemaker indications between the three groups. There was no significant difference in pacemaker implantation rate between the two groups receiving the CoreValve' in the PMA group versus the Pivotal Trial group (44.9% versus 40.0%; p ¼ 0.63). This is graphically depicted in Figure 1 . However, the Evolut' group had a rate of 22.2%. When the three groups are compared, the value did not reach statistical significance (p ¼ 0.12), but when the Evolut group is compared with the total CoreValve' population, this reached statistical significance (p ¼ 0.04) as shown in Figure 2 . Univariate analysis for the total population is depicted in Table 3 . When analysis was performed for the total population, only QTc and history of AF were found to be Figure 3 . A history of AF, the presence of RBBB, male gender, and AV nodal blocking drugs showed trends towards but failed to reach statistical significance. Multivariate analysis of the total population compared to subgroups is shown in Figure 4 . Factors were identified by prior univariate analysis. In the total population, prior conduction system disease and AF were demonstrated to be significant predictors of PPI (OR 2. 
Discussion
Our rate of PPI (39.3%) was similar to what is seen in the literature but somewhat higher. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 21, 24, 25 This may reflect differences in our population compared with the entire Pivotal Trial cohort or the general population post approval or perhaps a broader indication. The rate of high-grade AV block (complete heart block or Mobitz II second-degree block) was 22.9%. In our study, the PMA group was significantly younger than the Pivotal Trial group. In addition, the TAVR procedures completed in the PMA group were performed after the experience gained in the Pivotal Trial. Yet, the rate of PPI was not significantly different. This suggests that the CoreValve' has an effect on the cardiac conduction system independent of discernible patient risk factors. Furthermore, in our analysis only AF and prior conduction disease were shown to be significant risk factors for PPI. We postulate that the high pacemaker implantation risk of CoreValve' stems from a combination of mechanical disruption by the new valve in an already susceptible patient. More specifically, the self-expanding feature itself of the Medtronic CoreValve' system may play an important role in this mechanical disruption. The AV node is located on the central fibrous body in the muscular portion of the AV septum. The bundle of His extends from the AV node rightward. It then enters the posteroinferior portion of the membranous septum and the crest of the muscular septum, forming part of the left ventricular outflow tract (LVOT). 26 In an autopsy series of elderly patients, approximately 30% of subjects had a leftward AV bundle, and in 20% the bundle coursed just underneath the endocardium on the membranous septum. 27 The selfexpanding skirt of the Medtronic CoreValve' applies outward pressure over this area, which may put strain on the bundle of His and possibly the AV node, consequently Pacemaker Implant Post CoreValve System leading to mechanically injury. With this in mind, it is easy to see why patients with pre-existing conduction disease would be at particular risk for high-grade AV block post TAVR. It is no surprise that RBBB is the most powerful predictor for PPI, given the high likelihood of LBBB after Medtronic CoreValve' placement. 28 The depth of implantation in the LVOT is predictive of the rate of PPI with the Medtronic CoreValve'. 29 Thus, larger valves implanted (i.e. 31-mm valves) would result in a larger number of conduction system abnormalities. This mechanism is also supported by the increased rate of pacemaker implantation with the ESV S3 valve compared with the ESV XT valve, in which the stent and increase in mesh fabric extends further into the LVOT. 30 It is somewhat controversial whether PPI adversely affects long-term outcome and mortality after TAVR. 31 Data from the PARTNER study and registry demonstrate that PPI is associated with a longer hospital stay and risk of subsequent hospitalization. 28 The data also reveal an increase in the composite endpoint of death and repeat hospitalization. 28 There are many potential explanations for poorer outcome in patients requiring pacemaker implantation after TAVR. Certainly, this may be reflective of more advanced disease or significant comorbidities. Our data suggest that only pre-existing conduction system disease and AF are predictive of PPI. Patients in our PMA group were also younger than the Pivotal Trial recipients. Operator experience did not significantly alter PPI rates between the Pivotal Trial and PMA groups. Taken together, these data suggest that the risk of PPI may be more related to the CoreValve' device and implant procedure. Furthermore, given the high incidence of conduction disease among candidates for TAVR, risk stratification becomes more challenging. Our data demonstrate a significant decrease in PPI rate with the next generation Evolut' valve at 22.2%, which is similar to other published data. 32 This improvement is highly significant and represents an important advancement that will hopefully translate to long-term clinical benefits. However, heart block remains a significant complication of TAVR. Its impact including the potential for pacing-induced dyssynchrony leading to decline in left ventricular function has yet to be well delineated in this population. Recently, a meta-analysis of patients post TAVR with LBBB or PPI demonstrated a trend toward an increase in mortality with LBBB with a relative risk of 1.39, with early PPI negating this risk. 33 Periprocedural PPI itself was not associated with an increase in mortality. Post-TAVR LBBB and pacing-induced dyssynchrony may be reasons for worsened outcomes in this population. 34 Indeed, further investigation including whether or not cardiac resynchronization therapy has a role in this population needs to be pursued. Of equal importance is the need to determine whether or not unnecessary PPI post-TAVR is associated with worsened outcomes. The self-expanding nature of the CoreValve' system has led to the belief that early conduction system disturbances may simply predict future need for PPI and that early PPI may mitigate the risk of adverse events related to progressive conduction system disease. However, a recent report suggests that among patients with new LBBB post TAVR, the need for pacing for high-grade AV block is very low. 35 Thus, the potential for worsening outcomes with new LBBB is more likely secondary to ventricular dyssynchrony rather than progressive conduction system disease. Interestingly, a retrospective analysis of CoreValve' patients who developed post-TAVR heart block revealed a high percentage of patients with eventual conduction system recovery. 28, 36 This underscores the importance of determining when pacemaker implantation is absolutely necessary after TAVR. Studies such as the Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree AtrioVentricular Block in Patients With New-Onset Persistent Left Bundle Branch Block After Transcatheter Aortic Valve Implantation (MARE) study (NCT02153307) will hopefully provide answers to this question.
Study limitations
This was a retrospective analysis from a single center and thus subject to potential bias. However, the comparisons made were in subjects performed by the same operators and facility. In addition, the relatively small numbers may not allow for adequate power for subgroup analysis.
Conclusions
Our study demonstrates that the rate of PPI after postmarket approval of the Medtronic CoreValve' is no different from that of the Pivotal Trial. Antecedent conduction system disease and AF were the only predictors of pacemaker implantation, and the next generation Evolut' valve is associated with a decreased PPI rate. Further studies are needed to determine if this translates to better long-term clinical outcomes, and whether or not alternative strategies to mitigate the risks of conduction system abnormalities are effective.
